Maria Khouri

665 total citations
22 papers, 233 citations indexed

About

Maria Khouri is a scholar working on Public Health, Environmental and Occupational Health, Genetics and Oncology. According to data from OpenAlex, Maria Khouri has authored 22 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Public Health, Environmental and Occupational Health, 11 papers in Genetics and 8 papers in Oncology. Recurrent topics in Maria Khouri's work include Acute Lymphoblastic Leukemia research (18 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (7 papers). Maria Khouri is often cited by papers focused on Acute Lymphoblastic Leukemia research (18 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (7 papers). Maria Khouri collaborates with scholars based in United States. Maria Khouri's co-authors include Farhad Ravandi, Guillermo Garcia‐Manero, Elias Jabbour, Hagop M. Kantarjian, Nitin Jain, Marina Konopleva, Koji Sasaki, Jörge E. Cortes, Rebecca Garris and Tapan M. Kadia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Maria Khouri

21 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Khouri United States	9	170	143	102	56	41	22	233
Jovitta Jacob United States	6	233 1.4×	180 1.3×	141 1.4×	63 1.1×	70 1.7×	23	273
Monika Brüggemann Germany	8	240 1.4×	126 0.9×	135 1.3×	83 1.5×	106 2.6×	16	297
Catherine Tuglus United States	8	119 0.7×	110 0.8×	77 0.8×	31 0.6×	16 0.4×	12	193
Mohammed Wattad Germany	3	114 0.7×	81 0.6×	84 0.8×	22 0.4×	45 1.1×	5	200
Thomas Lipp Germany	7	140 0.8×	54 0.4×	92 0.9×	46 0.8×	42 1.0×	10	181
Sherry Pierce United States	4	222 1.3×	72 0.5×	262 2.6×	38 0.7×	38 0.9×	5	342
Walid Macaron United States	7	118 0.7×	91 0.6×	128 1.3×	22 0.4×	25 0.6×	22	181
Laura Kingsbury United States	6	143 0.8×	86 0.6×	161 1.6×	16 0.3×	26 0.6×	8	219
Christine Mauz‐Koerholz Germany	5	60 0.4×	75 0.5×	82 0.8×	79 1.4×	24 0.6×	17	190
Nikola Hagedorn Germany	6	223 1.3×	65 0.5×	158 1.5×	30 0.5×	97 2.4×	11	258

Countries citing papers authored by Maria Khouri

Since Specialization

Citations

This map shows the geographic impact of Maria Khouri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Khouri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Khouri more than expected).

Fields of papers citing papers by Maria Khouri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Khouri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Khouri. The network helps show where Maria Khouri may publish in the future.

Co-authorship network of co-authors of Maria Khouri

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Khouri. A scholar is included among the top collaborators of Maria Khouri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Khouri. Maria Khouri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khouri, Maria, Bofei Wang, Lloyd Hutchinson, et al.. (2025). Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 131(8). e35846–e35846. 1 indexed citations

Sasaki, Koji, Hagop M. Kantarjian, Kiyomi Morita, et al.. (2021). Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 127(18). 3381–3389. 16 indexed citations

Sasaki, Koji, Elias Jabbour, Ghayas C. Issa, et al.. (2020). Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood. 136(Supplement 1). 25–26. 4 indexed citations

Alatrash, Gheath, Na Qiao, Pariya Sukhumalchandra, et al.. (2019). Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clinical Cancer Research. 25(8). 2610–2620. 21 indexed citations

Alfayez, Mansour, Hagop M. Kantarjian, Nicholas J. Short, et al.. (2018). Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood. 132(Supplement 1). 2702–2702. 11 indexed citations

Jabbour, Elias, Koji Sasaki, Farhad Ravandi, et al.. (2018). Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage. Cancer. 124(20). 4044–4055. 76 indexed citations

Sasaki, Koji, Hagop M. Kantarjian, Nicholas J. Short, et al.. (2018). Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood. 132(Supplement 1). 34–34. 2 indexed citations

Bazarbachi, Abdul Hamid, Musa Yılmaz, Farhad Ravandi, et al.. (2018). A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. Journal of Clinical Oncology. 36(15_suppl). 7041–7041. 9 indexed citations

Kantarjian, Hagop M., Nicholas J. Short, Farhad Ravandi, et al.. (2018). Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 4017–4017. 6 indexed citations

10.

Rausch, Caitlin R., Shilpa Paul, Hagop M. Kantarjian, et al.. (2018). Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. Blood. 132(Supplement 1). 1417–1417. 1 indexed citations

11.

Kantarjian, Hagop M., Nicholas J. Short, Maria Khouri, et al.. (2018). Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. Blood. 132(Supplement 1). 5212–5212. 2 indexed citations

12.

Jabbour, Elias, Koji Sasaki, Farhad Ravandi, et al.. (2018). Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood. 132(Supplement 1). 2664–2664. 1 indexed citations

13.

Khouri, Maria, Elias Jabbour, Alison Gulbis, et al.. (2017). Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 23(8). 1405–1410. 5 indexed citations

14.

Maiti, Abhishek, Hagop M. Kantarjian, Farhad Ravandi, et al.. (2017). Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia.. Journal of Clinical Oncology. 35(15_suppl). 7033–7033. 3 indexed citations

15.

Maiti, Abhishek, Hagop M. Kantarjian, Farhad Ravandi, et al.. (2017). Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clinical Lymphoma Myeloma & Leukemia. 17. S256–S257. 1 indexed citations

16.

Short, Nicholas J., Hagop M. Kantarjian, Koji Sasaki, et al.. (2016). Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology. 92(3). 238–243. 33 indexed citations

17.

Issa, Ghayas C., Hagop M. Kantarjian, Farhad Ravandi, et al.. (2016). Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 34(15_suppl). 7042–7042. 1 indexed citations

18.

Chahoud, Jad, Hagop M. Kantarjian, Guillermo Garcia‐Manero, et al.. (2015). Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. Blood. 126(23). 1298–1298. 2 indexed citations

19.

Sasaki, Koji, Hagop M. Kantarjian, Susan O’Brien, et al.. (2015). Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood. 126(23). 3721–3721. 11 indexed citations

20.

Sasaki, Koji, Paul Koller, Hagop M. Kantarjian, et al.. (2015). Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood. 126(23). 1295–1295. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact